<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.fool.com.au/2019/11/25/goldman-sachs-tips-csl-share-price-to-hit-300/"/>
    <meta property="og:site_name" content="Motley Fool Australia"/>
    <meta property="article:published_time" content="2019-11-25T01:59:58+00:00"/>
    <meta property="og:title" content="Goldman Sachs tips CSL share price to hit $300"/>
    <meta property="og:description" content="On the back of the strong immunoglobulin sales Goldman's is forecasting EPS of US$5.53 in FY 2021. Are CSL shares a buy?"/>
  </head>
  <body>
    <article>
      <h1>Goldman Sachs tips CSL share price to hit $300</h1>
      <address><time datetime="2019-11-25T01:59:58+00:00">25 Nov 2019, 01:59</time> by <a rel="author" href="https://www.fool.com.au/author/tmfdelboy/" target="_blank">Tom Richardson</a></address>
      <p><b>CSL Limited</b> <a href="https://www.fool.com.au/company/CSL+Limited/?ticker=ASX-CSL">(ASX: CSL)</a> shares are up 1.2% to $272.89 on the back of a research note out of Goldman Sachs’ healthcare desk this morning. </p>
      <p>The analysts have crunched the numbers and taken another look at CSL’s business lines to come up with a bullish new price target.</p>
      <p>According to Goldman’s, CSL’s core immunoglobulin business is humming along with “market dynamics highly favourable”.</p>
      <p>The analysts are forecasting three-year compound annual sales growth rates of 13% and 17% for CSL’s core Privigen and Hizentra immunoglobulin products.</p>
      <p>Overall the analysts have upgraded their earnings per share forecasts by 4% on average though FY 2020 to FY 2022. Goldman’s is forecasting CSL to earn US$4.69 per share in FY 2020 to place it on 39.5x FX-adjusted EPS around $6.90.</p>
      <p>On the back of the strong immunoglobulin sales, Goldman’s is forecasting EPS of US$5.53 in FY 2021 to place it on 33.5x FX-adjusted EPS around $8.14.</p>
      <p>Goldman’s joins a number of other influential analysts including <b>UBS,</b> <b>Morgan Stanley</b> and <b>Credit Suisse </b>in delivering bullish price targets for CSL.</p>
      <p>Goldman’s also has a buy rating on<b> ResMed Inc.</b> <a href="https://www.fool.com.au/company/ResMed+Inc./?ticker=ASX-RMD">(ASX: RMD)</a> shares. </p>
    </article>
  </body>
</html>